Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Virology

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    November 2022
  1. SANTOS LA, Almeida F, Giria M, Trigueiro-Louro J, et al
    Adaptive evolution of PB1 from influenza A(H1N1)pdm09 virus towards an enhanced fitness.
    Virology. 2022;578:1-6.
    PubMed     Abstract available


    October 2022
  2. LIANG Y, Hjulsager CK, Seekings AH, Warren CJ, et al
    Pathogenesis and infection dynamics of high pathogenicity avian influenza virus (HPAIV) H5N6 (clade 2.3.4.4b) in pheasants and onward transmission to chickens.
    Virology. 2022;577:138-148.
    PubMed     Abstract available


  3. TANIKAWA T, Fujii K, Sugie Y, Tsunekuni R, et al
    Ubiquitin-specific protease 18 in mallard (Anas platyrhynchos) interferes with type I interferon-mediated inhibition of high pathogenicity avian influenza virus replication.
    Virology. 2022;577:32-42.
    PubMed     Abstract available


  4. BRAKEL KA, Ma Y, Binjawadagi R, Harder O, et al
    Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model.
    Virology. 2022;575:101-110.
    PubMed     Abstract available


  5. AMIDEI A, Dobrovolny HM
    Estimation of virus-mediated cell fusion rate of SARS-CoV-2.
    Virology. 2022;575:91-100.
    PubMed     Abstract available


  6. MONTEIRO A, Chang AJ, Welliver RR, Baron S, et al
    Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.
    Virology. 2022;575:83-90.
    PubMed     Abstract available


  7. POPOVIC M
    Strain wars 4 - Darwinian evolution through Gibbs' glasses: Gibbs energies of binding and growth explain evolution of SARS-CoV-2 from Hu-1 to BA.2.
    Virology. 2022;575:36-42.
    PubMed     Abstract available


    September 2022
  8. TANG CY, Boftsi M, Staudt L, McElroy JA, et al
    SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season.
    Virology. 2022;576:105-110.
    PubMed     Abstract available


  9. WANG R, Huang X, Cao T, Sun C, et al
    Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants.
    Virology. 2022;576:61-68.
    PubMed     Abstract available


  10. YAN H, Liu Z, Yan G, Liu X, et al
    A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors.
    Virology. 2022;574:18-24.
    PubMed     Abstract available


    August 2022
  11. ABDELKADER A, Elzemrany AA, El-Nadi M, Elsabbagh SA, et al
    In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Virology. 2022;573:96-110.
    PubMed     Abstract available


  12. AL-ZYOUD W, Haddad H
    Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
    Virology. 2022;573:84-95.
    PubMed     Abstract available


    July 2022
  13. WANG T, Wei F, Jiang Z, Song J, et al
    Influenza virus NS1 interacts with 14-3-3epsilon to antagonize the production of RIG-I-mediated type I interferons.
    Virology. 2022;574:47-56.
    PubMed     Abstract available


  14. HAN M, Gao S, Hu W, Zhou Q, et al
    Inhibitory effects of cedar pine needle extract on H9N2 avian influenza virus in vitro and in vivo.
    Virology. 2022;574:25-36.
    PubMed     Abstract available


  15. GE Y, Liu K, Chi Y, Zhu X, et al
    Exosomal microRNA expression profiles derived from A549 human lung cells in response to influenza A/H1N1pdm09 infection.
    Virology. 2022;574:9-17.
    PubMed     Abstract available


  16. OH J, Subbiah J, Kim KH, Park BR, et al
    Impact of hemagglutination activity and M2e immunity on conferring protection against influenza viruses.
    Virology. 2022;574:37-46.
    PubMed     Abstract available


  17. KUMAR P, Mathayan M, Smieszek SP, Przychodzen BP, et al
    Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
    Virology. 2022;572:64-71.
    PubMed     Abstract available


  18. PONDE RAA
    Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
    Virology. 2022;572:44-54.
    PubMed     Abstract available


    June 2022
  19. GUAN M, Jacobson O, Sarafianos G, Baroch J, et al
    Exposure of white-tailed deer in North America to influenza D virus.
    Virology. 2022;573:111-117.
    PubMed     Abstract available


  20. LIM H, Kim SE, Lee YH, Hwang YH, et al
    Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
    Virology. 2022;573:118-123.
    PubMed     Abstract available


  21. ZHU Y, Scholle F, Kisthardt SC, Xie DY, et al
    Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.
    Virology. 2022;571:21-33.
    PubMed     Abstract available


    May 2022
  22. KHAN K, Khan SA, Jalal K, Ul-Haq Z, et al
    Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
    Virology. 2022;572:28-43.
    PubMed     Abstract available


  23. ZMASEK CM, Lefkowitz EJ, Niewiadomska A, Scheuermann RH, et al
    Genomic evolution of the Coronaviridae family.
    Virology. 2022;570:123-133.
    PubMed     Abstract available


  24. POPOVIC M
    Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants.
    Virology. 2022;570:35-44.
    PubMed     Abstract available


  25. EL-ASHREY MK, Bakr RO, Fayed MAA, Refaey RH, et al
    Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease.
    Virology. 2022;570:18-28.
    PubMed     Abstract available


    April 2022
  26. PUCHINGER K, Castelletti N, Rubio-Acero R, Geldmacher C, et al
    The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 cases.
    Virology. 2022;569:37-43.
    PubMed     Abstract available


  27. MI T, Wang T, Xu H, Sun P, et al
    Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
    Virology. 2022;569:56-63.
    PubMed     Abstract available


  28. SARKAR L, Oko L, Gupta S, Bubak AN, et al
    Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict beta-coronaviral infection and replication.
    Virology. 2022;569:13-28.
    PubMed     Abstract available


  29. KAPCZYNSKI DR, Sweeney R, Spackman E, Pantin-Jackwood M, et al
    Development of an in vitro model for animal species susceptibility to SARS-CoV-2 replication based on expression of ACE2 and TMPRSS2 in avian cells.
    Virology. 2022;569:1-12.
    PubMed     Abstract available


    March 2022
  30. MOGRO EG, Bottero D, Lozano MJ
    Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic.
    Virology. 2022;568:56-71.
    PubMed     Abstract available


  31. XU H, Akinyemi IA, Chitre SA, Loeb JC, et al
    SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.
    Virology. 2022;568:13-22.
    PubMed     Abstract available


    February 2022
  32. CHEN X, Sun HY, Lee CY, Rostad CA, et al
    Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
    Virology. 2022;569:44-55.
    PubMed     Abstract available


    January 2022
  33. CHEN Z, Zeng Y, Wei Y, Wang Q, et al
    Influenza D virus Matrix protein 1 restricts the type I interferon response by degrading TRAF6.
    Virology. 2022;568:1-11.
    PubMed     Abstract available


  34. AFRIN SZ, Islam MT, Paul SK, Kobayashi N, et al
    Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021.
    Virology. 2022;565:29-37.
    PubMed     Abstract available


  35. SODERLUND-VENERMO M, Varma A, Guo D, Gladue DP, et al
    World Society for Virology first international conference: Tackling global virus epidemics.
    Virology. 2022;566:114-121.
    PubMed     Abstract available


  36. NADERI N, Rahimzadeh M
    Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
    Virology. 2022;566:106-113.
    PubMed     Abstract available


  37. RAYMONDA MH, Ciesla JH, Monaghan M, Leach J, et al
    Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Virology. 2022;566:60-68.
    PubMed     Abstract available


  38. KUMAR P, Bhardwaj T, Garg N, Giri R, et al
    Microsecond simulations and CD spectroscopy reveals the intrinsically disordered nature of SARS-CoV-2 spike-C-terminal cytoplasmic tail (residues 1242-1273) in isolation.
    Virology. 2022;566:42-55.
    PubMed     Abstract available


    December 2021
  39. PARK BR, Subbiah J, Kim KH, Kwon YM, et al
    Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Virology. 2021;566:143-152.
    PubMed     Abstract available


  40. HEINIMAKI S, Lampinen V, Tamminen K, Hankaniemi MM, et al
    Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Virology. 2021;566:89-97.
    PubMed     Abstract available


  41. HU Z, Chen JP, Xu JC, Chen ZY, et al
    A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
    Virology. 2021;566:56-59.
    PubMed     Abstract available


    November 2021
  42. TRIGUEIRO-LOURO J, Santos LA, Almeida F, Correia V, et al
    NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication.
    Virology. 2021;565:106-116.
    PubMed     Abstract available


  43. GONG SY, Chatterjee D, Richard J, Prevost J, et al
    Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
    Virology. 2021;563:134-145.
    PubMed     Abstract available


  44. RAI P, Chuong C, LeRoith T, Smyth JW, et al
    Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis.
    Virology. 2021;563:98-106.
    PubMed     Abstract available


  45. ABDELHAFIZ AS, Fouad MA, Sayed-Ahmed MM, Kamel MM, et al
    Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.
    Virology. 2021;563:74-81.
    PubMed     Abstract available


  46. HARDER OE, Martinez M, Niewiesk S
    Nonsteroidal anti-inflammatory drugs restore immune function to respiratory syncytial virus in geriatric cotton rats (Sigmodon hispidus).
    Virology. 2021;563:28-37.
    PubMed     Abstract available


    October 2021
  47. AHMED SM, Nasr MA, Elshenawy SE, Hussein AE, et al
    BCG vaccination and the risk of COVID 19: A possible correlation.
    Virology. 2021;565:73-81.
    PubMed     Abstract available


  48. ZHANG G, Ng F, Chen M
    Short-hairpin RNAs delivered by recombinant adeno-associated virus inhibited the replication of influenza A viruses in vitro.
    Virology. 2021;564:46-52.
    PubMed     Abstract available


  49. BYRD-LEOTIS L, Lasanajak Y, Bowen T, Baker K, et al
    SARS-CoV-2 and other coronaviruses bind to phosphorylated glycans from the human lung.
    Virology. 2021;562:142-148.
    PubMed     Abstract available


  50. TAGHIZADEH P, Salehi S, Heshmati A, Houshmand SM, et al
    Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains.
    Virology. 2021;562:63-73.
    PubMed     Abstract available


  51. DEUTSCHMANN-OLEK KM, Yue WW, Bezerra GA, Skern T, et al
    Defining substrate selection by rhinoviral 2A proteinase through its crystal structure with the inhibitor zVAM.fmk.
    Virology. 2021;562:128-141.
    PubMed     Abstract available


    September 2021
  52. WELCH M, Park J, Harmon K, Zhang J, et al
    Pathogenesis of a novel porcine parainfluenza virus type 1 isolate in conventional and colostrum deprived/caesarean derived pigs.
    Virology. 2021;563:88-97.
    PubMed     Abstract available


  53. VERMA J, Subbarao N
    Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
    Virology. 2021;561:107-116.
    PubMed     Abstract available


  54. PLAAS M, Seppa K, Gaur N, Kasenomm P, et al
    Age- and airway disease related gene expression patterns of key SARS-CoV-2 entry factors in human nasal epithelia.
    Virology. 2021;561:65-68.
    PubMed     Abstract available


    August 2021
  55. MENNE Z, Pliasas VC, Compans RW, Glover S, et al
    Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.
    Virology. 2021;562:197-208.
    PubMed     Abstract available


  56. NAEMI FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A, et al
    Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia.
    Virology. 2021;560:1-7.
    PubMed     Abstract available


    July 2021
  57. CHEN X, Rostad CA, Anderson LJ, Sun HY, et al
    The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
    Virology. 2021;559:1-9.
    PubMed     Abstract available


    June 2021
  58. ICHIMIYA T, Okamatsu M, Kinoshita T, Kobayashi D, et al
    Sulfated glycans containing NeuAcalpha2-3Gal facilitate the propagation of human H1N1 influenza A viruses in eggs.
    Virology. 2021;562:29-39.
    PubMed     Abstract available


  59. UEDA H, Yamakawa N, Takeuchi K
    Amino- and carboxyl-terminal ends of the bovine parainfluenza virus type 3 matrix protein are important for virion and virus-like particle release.
    Virology. 2021;561:17-27.
    PubMed     Abstract available


  60. SUN H, Liu J, Xiao Y, Duan Y, et al
    Pathogenicity of novel reassortant Eurasian avian-like H1N1 influenza virus in pigs.
    Virology. 2021;561:28-35.
    PubMed     Abstract available


  61. TERRY JS, Anderson LB, Scherman MS, McAlister CE, et al
    Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
    Virology. 2021;558:28-37.
    PubMed     Abstract available


  62. NAYAK K, Gottimukkala K, Kumar S, Reddy ES, et al
    Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.
    Virology. 2021;558:13-21.
    PubMed     Abstract available


    May 2021
  63. CASE JB, Winkler ES, Errico JM, Diamond MS, et al
    On the road to ending the COVID-19 pandemic: Are we there yet?
    Virology. 2021;557:70-85.
    PubMed     Abstract available


  64. DJUKIC T, Mladenovic M, Stanic-Vucinic D, Radosavljevic J, et al
    Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2.
    Virology. 2021;557:15-22.
    PubMed     Abstract available


    April 2021
  65. UPRETY T, Sreenivasan CC, Bhattarai S, Wang D, et al
    Isolation and development of bovine primary respiratory cells as model to study influenza D virus infection.
    Virology. 2021;559:89-99.
    PubMed     Abstract available


  66. WATERS K, Wan HJ, Han L, Xue J, et al
    Variations outside the conserved motifs of PB1 catalytic active site may affect replication efficiency of the RNP complex of influenza A virus.
    Virology. 2021;559:145-155.
    PubMed     Abstract available


  67. NOLAN KE, Baer LA, Karekar P, Nelson AM, et al
    Metabolic shifts modulate lung injury caused by infection with H1N1 influenza A virus.
    Virology. 2021;559:111-119.
    PubMed     Abstract available


  68. STAUFT CB, Lien CZ, Selvaraj P, Liu S, et al
    The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.
    Virology. 2021;556:96-100.
    PubMed     Abstract available


  69. DETSIKA MG, Ampelakiotou K, Grigoriou E, Psarra K, et al
    A novel ratio of CD8(+):B-cells as a prognostic marker of coronavirus disease 2019 patient progression and outcome.
    Virology. 2021;556:79-86.
    PubMed     Abstract available


  70. ZHIRNOV OP, Chlanda P
    The cleavage of spike protein capital EN, Cyrilliccapital A, Cyrillic0-->capital EN, Cyrilliccapital A, Cyrillic1/HA2 by trypsin permits activation of the M2 channel without its proteolytic cleavage in the influenza A virus.
    Virology. 2021;559:86-88.
    PubMed     Abstract available


    March 2021
  71. SEEKINGS AH, Warren CJ, Thomas SS, Mahmood S, et al
    Highly pathogenic avian influenza virus H5N6 (clade 2.3.4.4b) has a preferable host tropism for waterfowl reflected in its inefficient transmission to terrestrial poultry.
    Virology. 2021;559:74-85.
    PubMed     Abstract available


  72. WOLF JJ, Xia C, Studstill CJ, Ngo H, et al
    Influenza A virus NS1 induces degradation of sphingosine 1-phosphate lyase to obstruct the host innate immune response.
    Virology. 2021;558:67-75.
    PubMed     Abstract available


  73. XIE L, Yi K, Li Y
    SARS_CoV2 RBD gene transcription cannot be driven by CMV promoter.
    Virology. 2021;558:22-27.
    PubMed     Abstract available


  74. LU KT, Yamamoto T, McDonald D, Li W, et al
    U.S.-Japan cooperative medical sciences program: 22nd International Conference on Emerging Infectious Diseases in the Pacific Rim.
    Virology. 2021;555:71-77.
    PubMed     Abstract available


  75. TAKESHITA M, Nishina N, Moriyama S, Takahashi Y, et al
    Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
    Virology. 2021;555:35-43.
    PubMed     Abstract available


    February 2021
  76. NOMURA N, Matsuno K, Shingai M, Ohno M, et al
    Updating the influenza virus library at Hokkaido University -It's potential for the use of pandemic vaccine strain candidates and diagnosis.
    Virology. 2021;557:55-61.
    PubMed     Abstract available


  77. ABDEL-MONEIM AS, Abdelwhab EM, Memish ZA
    Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines.
    Virology. 2021;558:1-12.
    PubMed     Abstract available


  78. ISHIGAKI H, Nakayama M, Kitagawa Y, Nguyen CT, et al
    Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.
    Virology. 2021;554:97-105.
    PubMed     Abstract available


  79. REFAEY RH, El-Ashrey MK, Nissan YM
    Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Virology. 2021;554:48-54.
    PubMed     Abstract available


    January 2021
  80. FREIRE-PASPUEL B, Vega-Marino P, Velez A, Cruz M, et al
    Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis.
    Virology. 2021;553:154-156.
    PubMed     Abstract available


    December 2020
  81. MORE SA, Patil AS, Sakle NS, Mokale SN, et al
    Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    Virology. 2020;555:10-18.
    PubMed     Abstract available


  82. LI L, Liang Y, Hu F, Yan H, et al
    Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
    Virology. 2020;551:26-35.
    PubMed     Abstract available


  83. JIANG RD, Li B, Liu XL, Liu MQ, et al
    Bat mammalian orthoreoviruses cause severe pneumonia in mice.
    Virology. 2020;551:84-92.
    PubMed     Abstract available


    November 2020
  84. YU R, Tan S, Dan Y, Lu Y, et al
    Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection.
    Virology. 2020;553:131-134.
    PubMed     Abstract available


  85. POWELL JD, Abente EJ, Chang J, Souza CK, et al
    Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
    Virology. 2020;553:94-101.
    PubMed     Abstract available


  86. JONES LR, Manrique JM
    Quantitative phylogenomic evidence reveals a spatially structured SARS-CoV-2 diversity.
    Virology. 2020;550:70-77.
    PubMed     Abstract available


  87. DOBROVOLNY HM
    Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Virology. 2020;550:61-69.
    PubMed     Abstract available


  88. KISHKO M, Catalan J, Swanson K, DiNapoli J, et al
    Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
    Virology. 2020;550:21-26.
    PubMed     Abstract available


    September 2020
  89. NISSLY RH, Zaman N, Ibrahim PAS, McDaniel K, et al
    Influenza C and D viral load in cattle correlates with bovine respiratory disease (BRD): Emerging role of orthomyxoviruses in the pathogenesis of BRD.
    Virology. 2020;551:10-15.
    PubMed     Abstract available


  90. SEYED HOSSEINI E, Riahi Kashani N, Nikzad H, Azadbakht J, et al
    The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
    Virology. 2020;551:1-9.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: